Published May 18, 2021
BUFFALO, N.Y. -- A major limitation of treating breast cancer with a class of chemotherapeutic drugs known as anthracyclines is the development of cardiac damage in some patients.
A team of investigators from the University at Buffalo and Roswell Park Comprehensive Cancer Center has discovered a genetic link between the anthracycline drug doxorubicin and decline in cardiac function.
The manuscript, “CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin,” is the culmination of over five years of collaborative research and was published in the journal Cardio-Oncology.
In previous studies, researchers identified a link between changes in a gene known as CBR3 and the risk of anthracycline-related cardiac damage in survivors of pediatric cancers. For this study, the research team recruited 155 breast cancer patients at Roswell Park Comprehensive Cancer Center receiving treatment with doxorubicin.
92 of those patients had a specific form of variation in the CBR3 gene and received an echocardiogram before treatment with doxorubicin and six months after treatment. Those patients with the CBR3 gene variant exhibited changes in echocardiographic parameters suggestive of early anthracycline-related cardiac damage.
The identification of these genetic variants may pave the way for improved treatment surveillance and facilitate more informed therapeutic decision-making regarding cancer prevention and treatment.
Authors on the study:
Assistant Director, Communications and Alumni Relations